Cargando…

Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models

BACKGROUND: Prostate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate cancer. To date, various (18)F- and (68)Ga-labeled urea-based radiotracers for PET imaging of PSMA have been developed and entered clinical trials. Here, we describe an automated synthesis o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouvet, Vincent, Wuest, Melinda, Jans, Hans-Soenke, Janzen, Nancy, Genady, Afaf R., Valliant, John F., Benard, Francois, Wuest, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854855/ https://www.ncbi.nlm.nih.gov/pubmed/27142881 http://dx.doi.org/10.1186/s13550-016-0195-6

Ejemplares similares

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [(18)F]DCFPyL-PET: comparison to [(18)F]fluorocholine-PET
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

PSA-Stratified Performance of [(18)F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
por: Harsini, Sara, et al.
Publicado: (2022)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

The differential diagnostic value of dual-phase (18)F-DCFPyL PET/CT in prostate carcinoma
por: Tian, Aijuan, et al.
Publicado: (2022)

Short-duration dynamic [(18)F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [(18)F]DCFPyL PET/MR at 120 minutes
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting
por: Johnsson, Kerstin, et al.
Publicado: (2021)

A new automated and putatively versatile synthesis of the PSMA-ligand derivative [(18)F]DCFPyL using the FASTlab(TM) synthesizer
por: Hoareau, Raphaël, et al.
Publicado: (2022)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
por: Ferreira, Gonçalo, et al.
Publicado: (2019)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Torga, Gonzalo, et al.
Publicado: (2019)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Safali, Selim, et al.
Publicado: (2020)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Pathological predictors of (18)F‐DCFPyL prostate‐specific membrane antigen‐positive recurrence after radical prostatectomy
por: Perry, Elisa, et al.
Publicado: (2022)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

High uptake of (68)Ga-PSMA and (18)F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
por: Oliveira, Dennis, et al.
Publicado: (2020)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of (18)F-DCFPyL PET/CT Restaging
por: Liu, Wei, et al.
Publicado: (2020)

Non-prostate cancer tumours: incidence on (18)F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
por: Perry, Elisa, et al.
Publicado: (2022)

(18)F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
por: Metser, Ur, et al.
Publicado: (2022)

The diagnostic performance of (18)F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
por: Pang, Wenyang, et al.
Publicado: (2023)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

(18)F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
por: Metser, Ur, et al.
Publicado: (2021)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

(18)F DCFPyL PSMA avid biopsy proven subcutaneous capillary haemangioma as a malignancy mimic in the setting of biochemical recurrent prostate carcinoma
por: Dhillon, Manvinder, et al.
Publicado: (2022)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
por: Sun, Jiale, et al.
Publicado: (2021)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Head-to-Head Comparison of [(18)F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [(18)F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer
por: García-Zoghby, Laura, et al.
Publicado: (2023)

[(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
por: Glicksman, Rachel M, et al.
Publicado: (2020)

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted (18)F-DCFPyL Positron Emission Tomography Imaging
por: Werner, Rudolf A., et al.
Publicado: (2018)

Radiofluorination using aluminum-fluoride (Al(18)F)
por: McBride, William J, et al.
Publicado: (2013)

Copper-Mediated Radiofluorination of Arylstannanes with [(18)F]KF
por: Makaravage, Katarina J., et al.
Publicado: (2016)

[(18)F]DCFPyL PET/CT versus [(18)F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study
por: Oprea-Lager, Daniela-Elena, et al.
Publicado: (2023)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
por: Phillips, Ryan M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ivrnh0dh9ehoq62p4nu26kgns1